GlassScriptPhysician profile
Robin M Henson
NPI 1700035029
$3,656.07
in general payments reported to CMS, 2019-2025
37 companies · $439 in 2025
The $439 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,076 · 2022: $942 · 2023: $824 · 2024: $376 · 2025: $439.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,638.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,638.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,113.79 | 2021-2025 | |
| Lilly USA, LLC | $380.46 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Currax Pharmaceuticals LLC | $315.49 | 2021-2025 | Contrave, Onzetra Xsail, Nexletol |
| Pfizer INC. | $200.97 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $135.29 | 2021-2024 | Rexulti, Nuedexta |
| Antares Pharma, INC. | $129.92 | 2021-2024 | Xyosted |
| Janssen Pharmaceuticals, INC | $122.57 | 2022-2024 | Spravato |
| Teva Pharmaceuticals USA, INC. | $106.78 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $90.48 | 2021-2023 | Breztri |
| Novo Nordisk INC | $80.63 | 2023-2024 | Wegovy |
| Biohaven Pharmaceuticals, INC. | $79.98 | 2021 | |
| Axsome Therapeutics, INC. | $73.90 | 2023-2025 | Auvelity |
| Kowa Pharmaceuticals America, INC. | $70.61 | 2022 | |
| Daiichi Sankyo INC. | $67.17 | 2021-2024 | Injectafer |
| Biohaven Pharmaceutical Holding Company LTD. | $61.36 | 2022 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $59.25 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $53.60 | 2021-2022 | |
| Amgen INC. | $50.97 | 2021-2024 | Krystexxa, Repatha, Otezla |
| Alfasigma USA, INC. | $49.63 | 2021-2022 | |
| Acella Pharmaceuticals, LLC | $47.66 | 2022-2023 | NP Thyroid 60 |
| Eisai INC. | $34.88 | 2021 | |
| Ibsa Pharma INC. | $32.31 | 2023-2024 | Tirosint, Licart, Tirosint |
| Medtronic, INC. | $32.19 | 2023 | Intellis Adaptivestim, Venaseal |
| Bausch Health US, LLC | $31.32 | 2022 | |
| Exact Sciences Corporation | $29.89 | 2023-2025 | Cologuard Collection Kit |
| Genentech USA, INC. | $23.76 | 2021 | |
| Halozyme INC | $21.73 | 2023 | |
| Mayne Pharma Commercial LLC | $19.90 | 2025 | |
| Vivus LLC | $18.70 | 2023 | Qsymia |
| Astellas Pharma US INC | $18.35 | 2025 | Veozah |
| Glaxosmithkline, LLC. | $18.28 | 2023 | Arexvy, Shingrix |
| Azurity Pharmaceuticals, INC. | $15.57 | 2023 | Adthyza |
| Exeltis, USA INC. | $14.82 | 2025 | Slynd |
| Sunovion Pharmaceuticals INC. | $14.66 | 2021 | |
| Clarus Therapeutics INC. | $14.05 | 2021 | |
| Avanir Pharmaceuticals, INC. | $13.50 | 2022 | |
| Abbott Laboratories | $11.65 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Henson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.